Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors

scientific article

Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3346/JKMS.2017.32.7.1124
P932PMC publication ID5461316
P698PubMed publication ID28581269

P50authorHae-Sim ParkQ12597311
Yoo Seob ShinQ57325316
Dong-Ho NahmQ84969330
Ji Ho LeeQ88236931
Su Chin KimQ88236933
Hyunna ChoiQ88236935
Chang Gyu JungQ88236937
Ga-Young BanQ42428944
Young-Min YeQ42428945
P2093author name stringYoo Seob Shin
Ji Ho Lee
Young Min Ye
Dong Ho Nahm
Chang Gyu Jung
Ga Young Ban
Su Chin Kim
Hyunna Choi
P2860cites workInjection allergen immunotherapy for asthmaQ24236566
Allergen Immunotherapy: Past, Present, and FutureQ26765974
Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading SystemQ34097796
Adult patients may outgrow their asthma: a 25-year follow-up study.Q50961863
Subcutaneous immunotherapy in Northern Israel: efficacy and safety.Q51263059
Advantages and disadvantages of accelerated immunotherapy schedulesQ81625091
Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosisQ83386200
Serum-specific IgE and allergen immunotherapy in allergic childrenQ86955874
The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis: review of the evidenceQ86991980
Serum specific IgE: a biomarker of response to allergen immunotherapyQ95589693
Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis.Q35211932
Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden studyQ35533173
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus reportQ38090066
An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.Q38153965
The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis: review of the evidenceQ38169884
Immunotherapy: what lies beyondQ38192150
Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergensQ38192151
Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?Q38194290
Comparative efficacy and safety of subcutaneous versus sublingual immunotherapyQ38244667
International consensus on allergy immunotherapy.Q38544969
Assessing the safety of subcutaneous immunotherapy dose adjustmentsQ39819994
Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from TurkeyQ41096295
Characterisation of systemic reactions to subcutaneous immunotherapy with airborne allergens and classification according to WAO 2010.Q45376263
Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy.Q48030345
Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergyQ48713439
P275copyright licenseCreative Commons Attribution-NonCommercial 4.0 InternationalQ34179348
P6216copyright statuscopyrightedQ50423863
P433issue7
P921main subjectimmunotherapyQ1427096
allergic asthmaQ12301086
P304page(s)1124-1130
P577publication date2017-07-01
P1433published inJournal of Korean Medical ScienceQ24039955
P1476titleSubcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors
P478volume32

Search more.